Anida Pharma, Inc.

Multiple pediatric neuro-sensory diseases with high risk of life-long severe disability or death have no existing effective therapies. To address this unmet need Anida Pharma is developing a pipeline of treatments that utilize the potential of resolution biology toward novel treatment paradigms to prevent and restore neuro-sensory dysfunction. The company’s first target indication is Retinopathy of Prematurity. Follow-on indications include drug-induced hearing loss in chemotherapy treated children and neonatal brain injury. Learn more.